A Phase 2 interventional study of TD-1211 and Placebo in Opioid Induced Constipation, sponsored by Glycyx Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Glycyx Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Opioid-Induced Constipation with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Opioid-Induced Constipation · United States.
Among the 43 studies in Opioid-Induced Constipation with a site in United States, this one is the 27th largest by enrollment of the 40 interventional ones that give a count, is one of 10 that started in 2011, is one of 12 in phase 2, and was the 30th registered.
87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.
Browse Opioid-Induced Constipation studies →1 of the 43 studies in Opioid-Induced Constipation with a site in United States is open now. Recruiting first, the newest first:
BioDelivery Sciences International · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Opioid-Induced Constipation studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 20 · Phase 4 4
First in 2002; this study’s year is marked. 10 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is below the median of 119 across 68 interventional studies indexed under Opioid-Induced Constipation.
Median enrollment 227 across the 40 interventional studies, 8,800 across the 3 observational. Of the 38 that completed or were terminated, 23 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 43 have an industry lead sponsor. The 10 most frequent:
Glycyx Therapeutics is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Glycyx Therapeutics has 6 studies filed under Opioid-Induced Constipation — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Opioid-Induced Constipation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg TD-1211 once daily for 4 days followed by 10 mg for 14 days
Drug: TD-1211
5 mg TD-1211 once daily for 4 days followed by 15 mg for 14 days
Drug: TD-1211
5 mg TD-1211 once daily for 2 days followed by 10 mg for 14 days
Drug: TD-1211
5 mg TD-1211 once daily for 2 days followed by 15 mg for 14 days
Drug: TD-1211
2 mg TD-1211 once daily for 14 days
Drug: TD-1211 · Drug: Placebo
2.5 mg TD-1211 every 6 hours for 14 days
Drug: TD-1211 · Drug: Placebo
Capsules
Capsules
Safety and tolerability of TD-1211
Time frame: 14 days
Complete spontaneous bowel movements (CSBM); Spontaneous bowel movements (SBM)
Change from baseline in the weekly SBM and CSBM frequency
Time frame: Weekly assessments throughout Treatment Period
Plan to share: No — Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.
No publications or documents are linked to this record.
The record gives a start of Oct 2011, a primary completion of May 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axelopran
Glycyx Therapeutics